- <![CDATA[Nivolumab Plus SOC Therapy Shows Encouraging Disease Control in Grade Group 5 Prostate Cancer]]><![CDATA[The regimen produced a 2-year freedom from biochemical recurrence rate of 90.3% in grade group 5 prostate cancer.]]>onclive · 2mo ago↗ source
- <![CDATA[Five Under 5: Top Oncology Videos for the Week of 5/3]]><![CDATA[The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.]]>onclive · 2mo ago↗ source
- <![CDATA[ADCs Reshape the Future of Lung Cancer Care: From Second-Line Therapy to Earlier Intervention]]><![CDATA[Judy Wang, MD, discusses how ADCs are transforming NSCLC treatment with improved responses, biomarker-driven care, and CNS activity.]]>